|
1
|
Cesca M, Morosi L, Berndt A, Fuso Nerini
I, Frapolli R, Richter P, Decio A, Dirsch O, Micotti E, Giordano S,
et al: Bevacizumab-induced inhibition of angiogenesis promotes a
more homogeneous intratumoral distribution of paclitaxel, improving
the antitumor response. Mol Cancer Ther. 15:125–135. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brotto L, Brundage M, Hoskins P, Vergote
I, Cervantes A, Casado HA, Poveda A, Eisenhauer E and Tu D;
Gynecologic Cancer Intergroup Study of NCIC Clinical Trials Group
(NCIC CTG); European Organization for Research and Treatment of
Cancer - Gynecologic Cancer Group (EORTC-GCG); Grupo de
Investigación de Cáncer de Ovario (GEICO), . Randomized study of
sequential cisplatin-topotecan/carboplatin-paclitaxel versus
carboplatin-paclitaxel: Effects on quality of life. Support Care
Cancer. 24:1241–1249. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shah K, Gupta S, Ghosh J, Bajpai J and
Maheshwari A: Acute non-ST elevation myocardial infarction
following paclitaxel administration for ovarian carcinoma: A case
report and review of literature. J Cancer Res Ther. 8:442–444.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rawal G, Yadav S and Kumar R: Paclitaxel
induced acute ST elevation myocardial infarction: A Rare Case
Report. J Clin Diagn Res. 10:XD01–XD02. 2016.PubMed/NCBI
|
|
5
|
Kaakeh Y, Overholser BR, Lopshire JC and
Tisdale JE: Drug-induced atrial fibrillation. Drugs. 72:1617–1630.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tamargo J, Caballero R and Delpón E:
Drug-induced atrial fibrillation: Does it matter? Discov Med.
14:295–299. 2012.PubMed/NCBI
|
|
7
|
Tsim S, O'Dowd CA, Milroy R and Davidson
S: Staging of non-small cell lung cancer (NSCLC): A review. Respir
Med. 104:1767–1774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Théophile H, André M, Miremont-Salamé G,
Arimone Y and Bégaud B: Comparison of three methods (an updated
logistic probabilistic method, the Naranjo and Liverpool
algorithms) for the evaluation of routine pharmacovigilance case
reports using consensual expert judgement as reference. Drug Saf.
36:1033–1044. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Belhekar MN, Taur SR and Munshi RP: A
study of agreement between the Naranjo algorithm and WHO-UMC
criteria for causality assessment of adverse drug reactions. Indian
J Pharmacol. 46:117–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lombardi D, Crivellari D, Scuderi C, Magri
MD, Spazzapan S, Sorio R, Di Lauro V, Scalone S and Veronesi A:
Long-term, weekly one-hour infusion of paclitaxel in patients with
metastatic breast cancer: A phase II monoinstitutional study.
Tumori. 90:285–288. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Palma M, Mancuso A, Grifalchi F, Lugini A,
Pizzardi N and Cortesi E: Atrial fibrillation during adjuvant
chemotherapy with docetaxel: A case report. Tumori. 88:527–529.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moscetti L, Ramponi S, Maccaglia C,
Villanti P and Cortesi E: Atrial fibrillation in a patient with
non-small-cell carcinoma of the lung in the course of paclitaxel
therapy. Clin Ter. 149:377–379. 1998.(In Italian). PubMed/NCBI
|
|
13
|
National Cancer Institute: National Cancer
Institute Adverse Drug Reactions database. https://www.cancer.gov/.1993
|
|
14
|
Zamorano JL, Lancellotti P, Muñoz DR,
Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY,
Lyon AR, et al: ESC Position Paper on cancer treatments and
cardiovascular toxicity developed under the auspices of the ESC
Committee for Practice Guidelines. Kardiol Pol. 74:1193–1233.
2016.(In Polish). View Article : Google Scholar : PubMed/NCBI
|
